Geodon (ziprasidone), a new atypical antipsychotic for schizophrenia

Pfizer will soon market Geodon (ziprasidone), a new atypical antipsychotic for schizophrenia.

Geodon will be widely used because it appears to cause less weight gain than other atypicals...Zyprexa, Seroquel, or Risperdal.

This is important. Weight gain is a common reason why patients discontinue therapy...and it increases the risk of developing diabetes and heart disease.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote